Together, BIOTECanada and Canada’s Drug Agency (CDA-AMC) developed and tested a strategic foresight framework, offering key recommendations to guide the health system as it navigates the introduction of Advanced Therapeutic Products (ATPs). BIOTECanada members valued the opportunity to work with CDA-AMC to support system readiness for ATPs in Canada; this project represents a significant milestone in the collaboration between CDA-AMC and industry.
BIOTECanada